Carrier screening panels for Ashkenazi Jews: Is more better?

Genetics in Medicine

Volumn 7, Issue 3, 2005, Pages 185-190

  Leib, Jennifer R ^a,b   Gollust, Sarah E ^b,c   Hull, Sara Chandros ^b,c   Wilfond, Benjamin S ^b,c,d  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NONE   (United States)

Author keywords

Ashkenazi Jews; Carrier screening; Guidelines; Policy development; Stigmatization

Indexed keywords

ARTICLE; ASHKENAZI JEW; BLOOM SYNDROME; CANAVAN DISEASE; COST; CYSTIC FIBROSIS; DYSAUTONOMIA; FANCONI ANEMIA; GAUCHER DISEASE; GENETIC ANALYSIS; GENETIC SCREENING; HEALTH CARE POLICY; HETEROZYGOTE; HUMAN; INFORMATION DISSEMINATION; JEW; LABORATORY TEST; LIFESPAN; MUCOLIPIDOSIS; MUCOLIPIDOSIS TYPE 4; NIEMANN PICK DISEASE; PERCEPTION DEAFNESS; POPULATION RESEARCH; PRACTICE GUIDELINE; TAY SACHS DISEASE; TECHNIQUE;

EMPIRICAL APPROACH; GENETICS AND REPRODUCTION;

GENETIC DISEASES, INBORN; GENETIC SCREENING; GENETICS, POPULATION; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; JEWS; TAY-SACHS DISEASE;

EID: 16444383717     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.GIM.0000156527.87525.8F     Document Type: Article

References (28)

1. Rothenberg KH, Rutkin AB. Toward a framework of mutualism: the Jewish community in genetics research. Community Genet 1998;1:148-153.
2. Risch N, Tang H, Katzenstein H, Ekstein J. Geographic distribution of disease mutations in the Ashkenazi Jewish population supports genetic drift over selection. Am J Hum Genet 2003;72:812-822.
3. Zlotogora J, Bach G, Munnich A. Molecular basis of mendelian disorders among Jews. Mol Genet Metab 2000;69:169-180.
4. Kaplan F. Tay-Sachs disease carrier screening: a model for prevention of genetic disease. Genet Test 1998;2:271-292.
5. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. Tay-Sachs disease-carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA 1993;270:2307-2315.
6. Levin M. Screening Jews and genes: a consideration of the ethics of genetic screening within the Jewish community: challenges and responses. Genet Test 1999;3:207-213.
7. Gilbert F. Establishing criteria for a carrier detection panel: lessons from the Ashkenazi Jewish model. Genet Test 1998;2:301-304.
8. Goodman RM. Genetic Disorders Among the Jewish People. Baltimore: The Johns Hopkins University Press; 1979.
9. Abel EL. Jewish Genetic Disorders: A Layman's Guide. Jefferson, North Carolina: McFarland and Company, Inc; 2001.
10. Lehrman S. Jewish leaders seek genetic guidelines. Nature 1997;389:322.
11. Wadman M. Jewish leaders meet NIH chiefs on genetic stigmatization fears. Nature 1998;392:851.
12. Gollust SE, Hull SC, Wilfond BS. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA 2002;288:1762-1767.
13. Zinberg RE, Kornreich R, Edelmann L, Desnick RJ. Prenatal genetic screening in the Ashkenazi Jewish population. Clin Perinatal 2001;28:367-382.
14. Eng CM, Desnick RJ. Experiences in molecular-based prenatal screening for Ashkenazi Jewish genetic diseases. Adv Genet 2001;44:275-296.
15. Online Mendelian Inheritance in Man [Internet]. 2003. Available at: http://www.ncbi.nlm.nih.gov/Omim/
16. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 2002;111:477-500.
17. Ben-Yosef T, Ness SL, Madeo AC, et al. A mutation of PCDH15 among Ashkenazi Jews with the type 1 Usher syndrome. N Engl J Med 2003;348:1664-1670.
18. Ostrer H. A genetic profile of contemporary Jewish populations. Nat Rev Genet 2001;2:891-898.
19. Andrews LB, Fullarton JE, Holtzman NA, Motulsky AG. Assessing Genetic Risks. Washington, D.C. National Academy Press; 1994.
20. Goodman MJ, Goodman LE. The overselling of genetic anxiety. Hastings Cent Rep 1982;12:20-27.
21. Strom CM, Crossley B, Redman JB et al. Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet Med 2004;6:145-152.
22. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA 1993;270:2948-2954.
23. Holtzman NA, Watson MS. Promoting Safe and Effective Genetic Testing in the United States Final Report of the Task Force on Genetic Testing; 1997. Bethesa, MD.
24. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-154.
25. Ob-Gyns Offering Large-Scale Cystic Fibrosis ScreeningRepresents First Major Clinical Change from the Human Genome Project. American College of Obstetricians and Gynecologists. Available at: http://www.acog.org/from_home/ publications/press_releases/nrI2-12-01-2.cfm. Accessed May 16, 2003.
26. Vastag B. Cystic fibrosis gene testing a challenge: experts say widespread use is creating unnecessary risks. JAMA 2003;289:2923-2924.
27. Edelmann L, Dong J, Desnick RJ, Kornreich R. Carrier screening for mucolipidosis type IV in the American Ashkenazi Jewish population. Am J Hum Genet 2002;70:1023-1027.
28. Patterson M. Niemann-Pick Disease, Type C. GeneReviews [Internet database]. September 10, 2001. Available at: http://www.genetests.org. Accessed April 2003.